Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease
Dalowski F, Kramer M, Wermke M, et al.
Key Points:
Updated efficacy data of mesenchymal stromal cells (MSC) as salvage treatment option for patients with steroid-refractory acute Graft-versus-Host Disease (aGvHD)
Majority of patients received peripheral blood stem cells from HLA-identical donor and suffered from grade IV aGvHD, with 36-day median onset of developing aGvHD from time of transplantation
MSC infusion therapy plus immunosuppressive agents yielded response rate of 47% including 5 CR
Overall survival similar when compared with non-MSC treated historic cohort
Implications:
In combination with immunosuppressive agents, MSC infusion therapy effective treatment option for patients with steroid-refractory acute Graft-versus-Host Disease
View the original abstract on the ASH website.
